Immune-based interventions to prevent postnatal HIV-1 transmission Genevieve G. Fouda, Sallie R. Permar  Trends in Microbiology  Volume 22, Issue 8, Pages 425-427 (August 2014) DOI: 10.1016/j.tim.2014.04.009 Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 1 Maternal/infant antiretroviral prophylaxis in low- and middle-income countries. To reduce mother-to-child transmission (MTCT) to below 5%, at least 90% of HIV-1-infected women should be identified and provided with appropriate prophylaxis. In low- and middle-income countries, 37% of pregnant women received HIV testing and counselling in 2012, 62% of women known to be HIV-infected received antiretroviral prophylaxis (ARV) during pregnancy, and 49% received ARV during breastfeeding. 35% of infants born to HIV-infected women were tested for HIV during the first 2 months of life. Adapted from WHO/UNICEF/UNAIDS global update on HIV treatment 2013: results, impact and opportunities (http://apps.who.int/iris/bitstream/10665/85326/1/9789241505734_eng.pdf) and the 2013 UNAIDS report on global AIDS epidemics (http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf). Trends in Microbiology 2014 22, 425-427DOI: (10.1016/j.tim.2014.04.009) Copyright © 2014 Elsevier Ltd Terms and Conditions

Figure 2 Timing of potential immune-based interventions to prevent postnatal HIV-1 infections. Trends in Microbiology 2014 22, 425-427DOI: (10.1016/j.tim.2014.04.009) Copyright © 2014 Elsevier Ltd Terms and Conditions